Faur and colleagues [24] explored the predictive role of serum lipid levels, p53, and Ki-67 in breast cancer patients undergoing neoadjuvant chemotherapy (NAC), with a focus on the molecular subtypes of the disease. This evidence concerns the gene TP53 and breast carcinoma.